4DMedical (ASX:4DX) secured clearance from the US Food and Drug Administration for its IQ-UIP diagnostic tool, according to a Tuesday filing with the Australian bourse.
The product was designed to identify the presence of usual interstitial pneumonia, which is used to detect interstitial pulmonary fibrosis, the filing said.
Company shares surged almost 16% in recent Tuesday trade.